-
Mashup Score: 31Home | GPP HIV - 6 day(s) ago
The Global Parliamentary Platform on HIV and AIDS (GPP HIV) is a new inter-parliamentary forum bringing together legislators around the world to end HIV and AIDS. GPP HIV was launched in July 2024 at the International AIDS Conference (AIDS2024) with the support of over 300 members of parliament from over 40 countries. Since then, it has continued to grow. The platform has been founded by parliamentarian platforms such as the Global TB Caucus, the Global Equality Caucus and UNITE in partnership with
Source: www.gpphiv.orgCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 0
As the new cases and related deaths fall in sub-Saharan Africa, the virus is rearing its head elsewhere. What’s the cause? And the solution?
Source: www.npr.orgCategories: General Medicine News, General HCPsTweet-
#HIV is spiking in new hot spots. Here's what's being done to control it https://t.co/gx6qOMt0wu
-
-
Mashup Score: 11
Trials met efficacy success criteria for non-inferiority of DOR/ISL to comparator antiretroviral therapies in adults with virologically suppressed HIV-1 Safety profiles were generally comparable between DOR/ISL and other therapies in these trials Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from two pivotal Phase 3 trials of the investigational, once-daily, oral, two-drug, single-tablet regimen of doravirine/islatravir [DOR/ISL (100 mg/0.25 mg)] in adults with HIV-1 infection that is virologically suppressed on different antiretroviral therapy regimens [baseline antiretroviral therapy (bART)]; MK-8591A-051 or bictegravir/emtricitabine/tenofovir alafenamide i [BIC/FTC/TAF (50 mg/200 mg/25 mg)]; MK-8591A-052 . The success criterion for the primary efficacy hypothesis, as measured by the percentage of participants with HIV-1 RNA levels ≥50 copies/mL at Week 48, was met in both trials. DOR/ISL was demonstrated to be non-inferior
Source: www.merck.comCategories: General Medicine News, PayerTweet-
Learn more about our latest update in #HIV: https://t.co/n3fJ2NnVpm https://t.co/NR004Edkmk
-
-
Mashup Score: 5Breakthrough of the Year: A drug that prevents HIV infection, providing six months of protection per shot - 11 day(s) ago
As its 2024 Breakthrough of The Year, Science has named the development of lenacapavir – a promising new injectable drug that prevents HIV infection
Source: www.worldpharmanews.comCategories: General Medicine News, Allergy-ImmunologyTweet-
Breakthrough of the Year: A drug that prevents #HIV infection, providing six months of protection per shot https://t.co/hzS8QMWzr2 https://t.co/UK9fQXO6Sk
-
-
Mashup Score: 88Multimedia | Podcasts | In conversation with | The Lancet HIV - 12 day(s) ago
Peter Hayward, Editor-in-Chief and Adrian Gonzalez-Lopez, Senior Editor at The Lancet HIV, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy. A monthly audio companion to the journal, this podcast covers a broad range of topics, from treatments of children with HIV to COVID-19 and chemsex, the experiences of HIV among global Indigenous populations to intimate partner violence and women with HIV, and
Source: www.thelancet.comCategories: General Medicine News, Infectious DiseaseTweet-
This month also marks the 10th anniversary of The Lancet HIV. In this month´s editorial and podcast we try to reflect this past decade of advances but also persistent and unanswered issues. #HIV Podcast: https://t.co/UrMVB2QLzP https://t.co/Z76J5osiFs
-
-
Mashup Score: 10Gilead to test once-a-year HIV prevention shot - 13 day(s) ago
Gilead is going to start testing a drug it believes could prevent HIV infection with just a single shot every year.
Source: www.statnews.comCategories: General Medicine News, General HCPsTweet-
Gilead said that it will soon begin Phase 3 testing for a drug it believes could prevent #HIV infection with just a single shot every year. https://t.co/ZMOx1mE3WY
-
-
Mashup Score: 7Journal of the International AIDS Society | IAS HIV Research Journal | Wiley Online Library - 14 day(s) ago
Introduction Social network-based testing approaches (SNAs) encourage individuals (“test promoters”) to motivate sexual partners and/or those in their social networks to test for HIV. We conducted a…
Source: onlinelibrary.wiley.comCategories: General Medicine News, Infectious DiseaseTweet-
📰This meta-analysis by Choong and colleagues explores the effectiveness of social network-based testing approaches, in enhancing #HIV testing uptake. Read the full article here: https://t.co/Vojb5IsmRL https://t.co/zsLFNVVyiT
-
-
Mashup Score: 26
Improving the caring aspects of health-care worker behaviour is feasible in public health settings, enhances client experience, reduces missed appointments, and increases retention.
Source: www.thelancet.comCategories: General Medicine News, Infectious DiseaseTweet-
Can respect and kindness in healthcare improve #HIV outcomes? This trial in Zambia found person-centred care boosts retention, reduces missed visits, and transforms client experiences, although did not relate to improval on treatment success. https://t.co/XwTvk9s70x https://t.co/v5idlo4NCc
-
-
Mashup Score: 14In Memoriam: A. Cornelius Baker - 15 day(s) ago
Editor s Note: On November 14, 2024, we shared this blog post memorializing our friend A. Cornelius Baker. A c…
Source: www.hiv.govCategories: General Medicine News, HIV/AIDSTweet-
Tomorrow, Friday, December 13 at 10 am ET, there will be a celebration of life for A. Cornelius Baker, a tireless advocate in the #HIV, LGBTQ+, and global health communities. This service will be live streamed. Learn more about attending virtually: https://t.co/OIkClImghN https://t.co/W7Bkqrt2IX
-
-
Mashup Score: 5
A groundbreaking study published in Nature Medicine gives insight into what an HIV cure could look like during infancy
Source: mg.co.zaCategories: General Medicine News, Infectious DiseaseTweet-
🇿🇦 "What researchers learnt from five baby boys in KwaZulu-Natal about an #HIV cure" via @mailandguardian https://t.co/L9dB6rh2Xr
-
🌐 The IAS is honoured to be a partner of the Global Parliamentary Platform on HIV and AIDS (GPP HIV), a new inter-parliamentary forum bringing together legislators around the world to end #HIV and AIDS. 📲 GPP HIV has just launched its official website: https://t.co/WxUCdiLc9K https://t.co/jFBSsLtru9